Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans

S. Etuaful, B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, M. Wansbrough-Jones

Research output: Contribution to journalArticle

Abstract

Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerons. Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerons in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerons disease.

Original languageEnglish (US)
Pages (from-to)3182-3186
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume49
Issue number8
DOIs
StatePublished - Aug 2005

Fingerprint

Mycobacterium ulcerans
Buruli Ulcer
Streptomycin
Rifampin
Anti-Bacterial Agents
Growth
Therapeutics
Body Weight
Western Africa
Complementary Therapies
Ulcer
Polymerase Chain Reaction
Skin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. / Etuaful, S.; Carbonnelle, B.; Grosset, J.; Lucas, S.; Horsfield, C.; Phillips, R.; Evans, M.; Ofori-Adjei, D.; Klustse, E.; Owusu-Boateng, J.; Amedofu, G. K.; Awuah, P.; Ampadu, E.; Amofah, G.; Asiedu, K.; Wansbrough-Jones, M.

In: Antimicrobial Agents and Chemotherapy, Vol. 49, No. 8, 08.2005, p. 3182-3186.

Research output: Contribution to journalArticle

Etuaful, S, Carbonnelle, B, Grosset, J, Lucas, S, Horsfield, C, Phillips, R, Evans, M, Ofori-Adjei, D, Klustse, E, Owusu-Boateng, J, Amedofu, GK, Awuah, P, Ampadu, E, Amofah, G, Asiedu, K & Wansbrough-Jones, M 2005, 'Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans', Antimicrobial Agents and Chemotherapy, vol. 49, no. 8, pp. 3182-3186. https://doi.org/10.1128/AAC.49.8.3182-3186.2005
Etuaful, S. ; Carbonnelle, B. ; Grosset, J. ; Lucas, S. ; Horsfield, C. ; Phillips, R. ; Evans, M. ; Ofori-Adjei, D. ; Klustse, E. ; Owusu-Boateng, J. ; Amedofu, G. K. ; Awuah, P. ; Ampadu, E. ; Amofah, G. ; Asiedu, K. ; Wansbrough-Jones, M. / Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. In: Antimicrobial Agents and Chemotherapy. 2005 ; Vol. 49, No. 8. pp. 3182-3186.
@article{88c6060ed790417297bd0cfefa02f753,
title = "Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans",
abstract = "Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerons. Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerons in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerons disease.",
author = "S. Etuaful and B. Carbonnelle and J. Grosset and S. Lucas and C. Horsfield and R. Phillips and M. Evans and D. Ofori-Adjei and E. Klustse and J. Owusu-Boateng and Amedofu, {G. K.} and P. Awuah and E. Ampadu and G. Amofah and K. Asiedu and M. Wansbrough-Jones",
year = "2005",
month = "8",
doi = "10.1128/AAC.49.8.3182-3186.2005",
language = "English (US)",
volume = "49",
pages = "3182--3186",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans

AU - Etuaful, S.

AU - Carbonnelle, B.

AU - Grosset, J.

AU - Lucas, S.

AU - Horsfield, C.

AU - Phillips, R.

AU - Evans, M.

AU - Ofori-Adjei, D.

AU - Klustse, E.

AU - Owusu-Boateng, J.

AU - Amedofu, G. K.

AU - Awuah, P.

AU - Ampadu, E.

AU - Amofah, G.

AU - Asiedu, K.

AU - Wansbrough-Jones, M.

PY - 2005/8

Y1 - 2005/8

N2 - Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerons. Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerons in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerons disease.

AB - Mycobacterium ulcerans disease is common in some humid tropical areas, particularly in parts of West Africa, and current management is by surgical excision of skin lesions ranging from early nodules to extensive ulcers (Buruli ulcer). Antibiotic therapy would be more accessible to patients in areas of Buruli ulcer endemicity. We report a study of the efficacy of antibiotics in converting early lesions (nodules and plaques) from culture positive to culture negative. Lesions were excised either immediately or after treatment with rifampin orally at 10 mg/kg of body weight and streptomycin intramuscularly at 15 mg/kg of body weight daily for 2, 4, 8, or 12 weeks and examined by quantitative bacterial culture, PCR, and histopathology for M. ulcerons. Lesions were measured during treatment. Five lesions excised without antibiotic treatment and five lesions treated with antibiotics for 2 weeks were culture positive, whereas three lesions treated for 4 weeks, five treated for 8 weeks, and three treated for 12 weeks were culture negative. No lesions became enlarged during antibiotic treatment, and most became smaller. Treatment with rifampin and streptomycin for 4 weeks or more inhibited growth of M. ulcerons in human tissue, and it provides a basis for proceeding to a trial of antibiotic therapy as an alternative to surgery for early M. ulcerons disease.

UR - http://www.scopus.com/inward/record.url?scp=23044451316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044451316&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.8.3182-3186.2005

DO - 10.1128/AAC.49.8.3182-3186.2005

M3 - Article

C2 - 16048922

AN - SCOPUS:23044451316

VL - 49

SP - 3182

EP - 3186

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -